Evidence map›Paper›PMID 27147512›Full record

ReviewWorld journal of urology2017

Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage.

J J Wendler, R Ganzer, B Hadaschik, A Blana, T Henkel, K U Köhrmann, S Machtens, A Roosen, G Salomon, L Sentker and 6 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

J J WendlerDepartment of Urology and Pediatric Urology, Magdeburg University Medical Center, Leipziger Str. 44, 39120, Magdeburg, Germany. johann.wendler@med.ovgu.de.
R GanzerDepartment of Urology, University of Leipzig, Leipzig, Germany.
B HadaschikDepartment of Urology, Ruprecht-Karls University, Heidelberg, Germany.
A BlanaDepartment of Urology and Pediatric Urology, Medical Center Fürth, Nuremberg, Germany.
T HenkelUrological Practice of Dr. Henkel and Dr. Kahmann, Berlin, Germany.
K U KöhrmannDepartment of Urology, St. Theresa Hospital, Mannheim, Germany.
S MachtensDepartment of Urology, St. Maria Hospital, Bergisch-Gladbach, Germany.
A RoosenDepartment of Urology, Augusta-Krankenanstalt gGmbH Bochum, Bochum, Germany.
G SalomonMartini Clinic, Hamburg-Eppendorf University Medical Center, Hamburg, Germany.
L SentkerJoint Urological Practice, Sinsheim, Germany.
U WitzschDepartment of Urology and Pediatric Urology, Northwest Hospital & Medical Center, Frankfurt/Main, Germany.
H P SchlemmerDepartment of Radiology, German Cancer Research Center, Heidelberg, Germany.
D BaumunkDepartment of Urology and Pediatric Urology, Magdeburg University Medical Center, Leipziger Str. 44, 39120, Magdeburg, Germany.
J KöllermannInstitute of Pathology, Sana Medical Center Offenbach, Offenbach, Germany.
M SchostakDepartment of Urology and Pediatric Urology, Magdeburg University Medical Center, Leipziger Str. 44, 39120, Magdeburg, Germany.
U B LiehrDepartment of Urology and Pediatric Urology, Magdeburg University Medical Center, Leipziger Str. 44, 39120, Magdeburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Irreversible electroporation (IRE), a new tissue ablation procedure available since 2007, could meet the requirements for ideal focal therapy of prostate cancer with its postulated features, especially the absence of a thermal ablation effect. Thus far, there is not enough evidence of its effectiveness or adverse effects to justify its use as a definitive treatment option for localized prostate cancer. Moreover, neither optimal nor individual treatment parameters nor uniform endpoints have been defined thus far. No advantages over established treatment procedures have as yet been demonstrated. Nevertheless, IRE is now being increasingly applied for primary prostate cancer therapy outside clinical trials, not least through active advertising in the lay press. This review reflects the previous relevant literature on IRE of the prostate or prostate cancer and shows why we should not adopt IRE as a routine treatment modality at this stage.

Indexed as

Ablation TechniquesElectroporationHumansMaleProstatic NeoplasmsTreatment OutcomeAblationDefinitive treatmentFocal therapyIrreversible electroporationLocalized prostate cancerProstate

Identifiers

PMID27147512

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.